Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 1048-1055

  Hernandez Luna, Marco A ^a,b   Rocha Zavaleta, Leticia ^c   Vega, Mario I ^d   Huerta Yepez, Sara ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Bcl xL, chemoresistance; HIF 1 ; Non Hodgkin lymphoma

Indexed keywords

2 METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

APOPTOSIS; BCL-X PROTEIN; CELL HYPOXIA; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOMA, NON-HODGKIN; PHENOTYPE; UP-REGULATION;

EID: 84876246911     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.733874     Document Type: Article

References (39)

1. Chatenoud L, Bertuccio P, Bosetti C, et al. Childhood cancer mortality in America, Asia, and Oceania, 1970 through 2007. Cancer 2010;116:5063-5074.
2. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-285.
3. Sandlund JT, Pui CH, Mahmoud H, et al. Effcacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol 2011;22:468-471.
4. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005;23:541-547.
5. Soltani-Arabshahi R, Leboeuf C, Rivet J, et al. Bcl-xLgeneexpression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL. J Invest Dermatol 2009; 129: 1703-1709.
6. Zhao WL, Daneshpouy ME, Mounier N, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004; 103: 695-697.
7. Lebedeva I, Rando R, Ojwang J, et al. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000; 60: 6052-6060.
8. Villedieu M, Louis MH, Dutoit S, et al. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 2007;105:31-44.
9. Wang R, Lin F, Wang X, et al. Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells. Cancer Chemother Pharmacol 2008;61:943-952.
10. Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation oficaspases. J Biol Chem 1999; 274: 13298-13304.
11. Arnold AA, Aboukameel A, Chen J, et al. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008; 7: 20.
12. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000;20:2687-2695.
13. Vega MI, Jazirehi AR, Huerta-Yepez S, et al. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005;175:2174-2183.
14. Chen N, Chen X, Huang R, et al. BCL-xLis atargetgeneregulated by hypoxia-inducible factor-1{alpha}. J Biol Chem 2009;284: 10004-10012.
15. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375.
16. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011; 14: 191-201.
17. Evens AM, Sehn LH, Farinha P, et al. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010;28:1017-1024.
18. Giatromanolaki A, Koukourakis MI, Pezzella F, et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008; 26: 219-224.
19. Li B, Takeda K, Yokoyama S, et al. A prolyl-hydroxylase inhibitor, ethyl-3, 4-dihydroxybenzoate, induces haem oxygenase-1 expression in human cells through a mechanism independent of hypoxia-inducible factor-1alpha. J Biochem 2008;144:643-654.
20. Mueck AO, Seeger H. 2-Methoxyestradiol-biologyandmechanism of action. Steroids 2010;75:625-631.
21. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000;65:95-106.
22. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989-1000.
23. Amundson SA, Myers TG, Scudiero D, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60: 6101-6110.
24. Qiao Q, Nozaki Y, Sakoe K, et al. NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma. Exp Hematol 2010;38:1199-1208.
25. Evens AM, Schumacker PT, Helenowski IB, et al. Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 2008; 141: 676-680.
26. Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001;20:5779-5788.
27. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
28. Park SS, Kim MA, Eom YW, et al. Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe. Biochem Biophys Res Commun 2007;363:1044-1049.
29. Park J, Franco RS, Augsburger JJ, et al. Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma. Curr Eye Res 2007;32:659-667.
30. Jazirehi AR, Vega MI, Chatterjee D, et al. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 2004; 64: 7117-7126.
31. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48:673-683.
32. Bu S, Blaukat A, Fu X, et al. Mechanisms for 2-methoxyest-radiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002; 531: 141-151.
33. Attalla H, Westberg JA, Andersson LC, et al. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 1998; 247: 616-619.
34. Joubert A, Maritz C, Joubert F. Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. Biomed Res 2005;26:131-134.
35. Piret JP, Minet E, Cosse JP, et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 2005;280:9336-9344.
36. Gao N, Rahmani M, Dent P, et al. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005; 24: 3797-3809.
37. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-1545.
38. Iqbal S, Zhang S, Driss A, et al. PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-1alpha-dependent signaling in human prostate cancer cells. PLoS One 2012;7:e30764.
39. Lee KB, Byun HJ, Park SH, et al. CYR61 controls p53 and NF-kappaB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett 2012; 315: 86-95.